Previous 10 | Next 10 |
Fusion Pharmaceuticals (FUSN) announces that the U.S. FDA has cleared the company's Investigational New Drug ((IND)) applications for FPI-1966 and imaging agent FPI-1967. Shares up more than 10% post market.FPI-1966 is a targeted alpha therapy ((TAT)) designed to use ...
Fusion Pharmaceuticals Announces FDA Clearance of IND for FPI-1966, an Investigational Radiopharmaceutical for the Treatment of Head and Neck and Bladder Cancers Expressing FGFR3 Canada NewsWire HAMILTON , ON and BOSTON , July 28, 2021 /CNW/ -- Fusi...
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Canada NewsWire HAMILTON, Ontario and BOSTON , July 7, 2021 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on devel...
Gainers: Opthea (OPT) +47%, Kindred Biosciences (KIN) +45%, Aprea Therapeutics (APRE) +38%, Altimmune (ALT) +21%, BriaCell Therapeutics (BCTX) +15%.Losers: Inhibikase Therapeutics (IKT) -24%, Paratek Pharmaceuticals (PRTK) -14%,...
Gainers: Clearside Biomedical (CLSD) +30%, Eloxx Pharmaceuticals (ELOX) +15%, Fusion Pharmaceuticals (FUSN) +14%, Precipio (PRPO) +14%, Ocugen (OCGN) +11%.Losers: PDS Biotechnology (PDSB) -27%, Sage Therapeutics (SAGE) -16%, Neu...
Clearside Biomedical (CLSD) +52% after positive results from early-stage wet AMD trial.Torchlight Energy Resources (TRCH) +33% after declaring special preferred dividend.Unique Fabricating (UFAB) +29%.Ocugen (OCGN) +20% after securing manufacturing partnership for COVAXIN in th...
Canberk Sezer/iStock via Getty Images Fusion Pharmaceuticals (FUSN) has climbed ~15.8% in the post-market after the company announced preliminary Phase 1 data for its radioimmunoconjugate FPI-1434 in solid tumors. The results from the first three patient cohorts (n=12) of the s...
Fusion Pharmaceuticals Announces Preliminary Safety and Dosimetry Results from its Single-Dose Portion of the Phase 1 Study of FPI-1434 Canada NewsWire Product candidate FPI-1434, administered at three different dose levels, demonstrated a favorable safety prof...
Fusion Pharmaceuticals (FUSN) announces the appointment of Isabelle Dussault as the company's senior vice president, research.She brings deep oncology research experience, including antibody-drug conjugate, biomarker and immuno-oncology expertise to Fusion's team.Dussault was m...
Fusion Pharmaceuticals Appoints Isabelle Dussault, Ph.D. as Senior Vice President, Research Canada NewsWire HAMILTON , ON and BOSTON, June 7, 2021 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on dev...
News, Short Squeeze, Breakout and More Instantly...
Fusion Pharmaceuticals Inc. Company Name:
FUSN Stock Symbol:
NASDAQ Market:
Fusion Pharmaceuticals Inc. Website:
Acquisition of Fusion Pharmaceuticals Completed Canada NewsWire HAMILTON , ON and BOSTON , June 4, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs), a...
Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement Canada NewsWire HAMILTON , ON and BOSTON , May 31, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation ...
Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca Canada NewsWire HAMILTON, ON and BOSTON , May 29, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiocon...